Sign in

LIANY on OTC

LianBio

LianBio is a pharmaceutical preparations company in the Cayman Islands.1 It is headquartered in Princeton, New Jersey.1 Its shares trade on OTC under the symbol LIANY.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerLIANY on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersPrinceton, New Jersey1
  • Incorporated inCayman Islands2
  • Business address103 Carnegie Center Drive, Suite 309, Princeton, Nj 085402
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34-$125.4M in 2022−7% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$134.9M-$134.9M20202021: -$195.6M-$195.6M2021+45%2022: -$125.4M-$125.4M2022−36%
Net income34-$110.3M in 2022−21% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$139.6M-$139.6M20202021: -$196.3M-$196.3M2021+41%2022: -$110.3M-$110.3M2022−44%
Fiscal year20192020202120222023
Research and development$120.9M3$158.7M4$59.8M4
Operating expenses$195.6M4$125.4M4
Operating income-$134.9M3-$195.6M4-$125.4M4
Income before tax-$195.8M4-$110.6M4
Income tax$4.0K3$518.0K4-$333.0K4
Net income-$139.6M3-$196.3M4-$110.3M4
Earnings per share-$11.583-$5.714-$1.024
Earnings per share (diluted)-$11.583-$5.714-$1.024
Shares (weighted, basic)34.4M shares4107.9M shares4
Shares (weighted, diluted)34.4M shares4107.9M shares4

Compare LianBio with another company

Corporate structure

LianBio sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of LianBio

  • LianBio Princeton, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LianBio reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.7M4 Dec 31, 2022$2.5M4 Dec 31, 2021+87.4%
Accumulated depreciation$1.5M4 Dec 31, 2022$606.0K4 Dec 31, 2021+155.3%
Property and equipment, net$3.1M4 Dec 31, 2022$1.9M4 Dec 31, 2021+65.6%
Operating-lease assets (leased space)$4.0M4 Dec 31, 2022$4.8M4 Dec 31, 2021−16.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$79.2M4 Dec 31, 2022$228.2M4 Dec 31, 2021−65.3%
Marketable securities, current$223.1M4 Dec 31, 2022$155.1M4 Dec 31, 2021+43.9%
Debt securities available for sale$223.1M4 Dec 31, 2022$155.1M4 Dec 31, 2021+43.9%

Leadership

Who has led LianBio, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yizhe Wang2021–2023
  2. Adam Leo Stone2024

Chief financial officer

  1. Yi Larson2021–2023
  2. Ehong Gu2023–2024
2025
  • Chief executive officerAdam Leo Stone Feb 20, 2024 to Feb 20, 20247
  • Chief executive officerYizhe Wang Oct 29, 2021 to Mar 31, 20238
  • Chief financial officerEhong Gu Dec 26, 2023 to Apr 11, 20249
  • Chief financial officerYi Larson Oct 29, 2021 to Mar 31, 202310
Board members and other officers (10)

Timeline

  1. Feb 20, 2024New chief executive Adam Leo Stone becomes CEO7
  2. Feb 13, 20248-K Exit or restructuring costs; Listing notice or transfer; Regulation FD disclosure20
  3. Dec 26, 20238-K Entered a material agreement; Ended a material agreement21
  4. Dec 20, 20238-K Executive or director change; Regulation FD disclosure22
  5. Dec 19, 20238-K Executive or director change; Regulation FD disclosure23
  6. Dec 6, 20238-K Regulation FD disclosure24
  7. Dec 1, 20238-K Other events25
  8. Nov 13, 20238-K Results of operations26
  9. Oct 30, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale27
  10. Aug 14, 20238-K Results of operations28
  11. Jun 23, 20238-K Shareholder vote29
  12. May 11, 20238-K Results of operations30
  13. May 1, 20238-K Regulation FD disclosure31
  14. Oct 29, 2021New chief executive Yizhe Wang becomes CEO8

Calendar

When it reported results

  1. Nov 13, 2023Reported quarterly or annual results26
  2. Aug 14, 2023Reported quarterly or annual results28
  3. May 11, 2023Reported quarterly or annual results30
  4. Mar 27, 2023Reported quarterly or annual results32
  5. Nov 10, 2022Reported quarterly or annual results33
  6. Aug 11, 2022Reported quarterly or annual results34
  7. May 12, 2022Reported quarterly or annual results35
  8. Mar 30, 2022Reported quarterly or annual results36

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

154 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 29 major events, 57 insider forms, 9 large holders, 49 other. The latest 20:

  1. Nov 14, 2024SC 13G EDGAR
  2. Apr 11, 20244 EDGAR
  3. Mar 21, 202415-12G EDGAR
  4. Mar 12, 2024EFFECT EDGAR
  5. Mar 12, 2024S-8 POS EDGAR
  6. Mar 12, 2024S-8 POS EDGAR
  7. Mar 12, 2024S-8 POS EDGAR
  8. Mar 12, 2024POS AM EDGAR
  9. Mar 11, 202425 EDGAR
  10. Feb 29, 2024SC 13D/A EDGAR
  11. Feb 20, 20244 EDGAR
  12. Feb 20, 20244 EDGAR
  13. Feb 20, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Feb 20, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. Feb 20, 20244 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. Feb 13, 20248-K EDGAR
  17. Jan 8, 2024144 EDGAR
  18. Dec 29, 2023144 EDGAR
  19. Dec 26, 20233 EDGAR
  20. Dec 26, 20238-K EDGAR

The 154 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 2, 2024Gu EhongInterim CFOSale1,731$4.34$7.5KForm 4
Jan 3, 2023QIAN JIANGSVP, China General ManagerSale2,239$1.65$3.7KForm 4
Aug 18, 2022LEV LB Holdings GP, LLCDirectorBuy998,240$2.40$2.4MForm 4
May 26, 2022LEV LB Holdings, LPDirectorBuy69,000$3.13$216.0KForm 4
May 25, 2022Perceptive Venture Advisors, LLCDirectorBuy120,000$2.63$315.6KForm 4
May 24, 2022Perceptive Venture Advisors, LLCDirectorBuy42,551$2.47$105.1KForm 4
May 23, 2022Perceptive Venture Advisors, LLCDirectorBuy8,700$2.49$21.7KForm 4
Nov 3, 2021LEV LB Holdings, LPDirectorBuy2,270,000$15.98$36.3MForm 4
Nov 2, 2021Perceptive Venture Advisors, LLCDirectorBuy100,000$13.50$1.4MForm 4
Nov 1, 2021Perceptive Venture Advisors, LLCDirectorBuy120,000$15.50$1.9MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How LianBio is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLianBio1
  • CIK0001831283
  • Filer status<br>emerging growth company1
  • Incorporated inCayman Islands1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address103 Carnegie Center Drive, Suite 309, Princeton, NJ 085401
  • Phone(609) 486-23081
  • Shares outstanding108,062,638 as of Nov 9, 20236
  • Public float$97.3M as of Jun 30, 20224
  • On EDGAR sinceNov 12, 20201
  • Filings170 in all: 4 (42), 8-K (29), 3 (14), CORRESP (9), UPLOAD (9), 10-Q (7), EFFECT (4), S-1/A (4)1
    All 38 form types

    SC 13G (4), DEFA14A (3), DRS/A (3), DRSLTR (3), S-3/A (3), S-8 (3), S-8 POS (3), 10-K (2), 144 (2), D (2), DEF 14A (2), SC 13D (2), SC 13G/A (2), SEC STAFF LETTER (2), 10-Q/A (1), 15-12G (1), 25 (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEFR14A (1), DRS (1), F-6 (1), F-6 POS (1), F-6/A (1), POS AM (1), S-1 (1), S-3 (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2023
    Quarterly report (10-Q) Nov 13, 2023
    Proxy statement (DEF 14A) Apr 19, 2023
    Latest 8-K (8-K) Feb 13, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41